Navigation Links
Ikaria® Appoints Chief Medical Officer
Date:4/11/2012

HAMPTON, N.J., April 11, 2012 /PRNewswire/ -- Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that Joseph Stauffer, D.O., has been appointed Chief Medical Officer.  In this role, Dr. Stauffer will be responsible for all medical, patient safety, risk management, and regulatory activities related to Ikaria's commercialized product, INOMAX® (nitric oxide) for inhalation, as well as future launch products.

"We are delighted to welcome Joe, whose extensive medical leadership experience will be of great benefit to the many aspects of our unique INOMAX offering," commented Daniel Tasse, Chairman and CEO of Ikaria. "We believe his previous experience in pharmaceuticals and at the FDA provide him with a unique opportunity to view our products with an exquisite balance of medical insight, business acumen and regulatory compliance."

Dr. Stauffer most recently held the position of Chief Medical Officer at PharmacoFore, a California-based biopharmaceutical company.  Prior to that, he was Chief Medical Officer at DURECT Corporation, a specialty pharmaceutical company, and at Alpharma/King Pharmaceuticals.  He began his pharmaceutical career at Abbott Laboratories in 2002, where he was global medical director for its pain portfolio.  Dr. Stauffer also served as a medical officer in the Analgesic Division of the FDA's Center for Drug Evaluation and Research from 2000-2002, where he reviewed Investigational New Drug (IND) Applications and New Drug Applications (NDAs) for opiate, non-opiate, anti-inflammatory and novel pain compounds.  He graduated from the Philadelphia College of Osteopathic Medicine and completed residency training in Anesthesiology at the Johns Hopkins University Hospital where he is currently an Adjunct Assistant Professor in the Department of Anesthesiology and Critical Care Medicine. Additionally, he completed his MBA as part of the TRIUM Global Executive MBA Program, a joint degree granted by NYU Stern School of Business, HEC School of Management (Paris) and the London School of Economics and Political Science.  Dr. Stauffer is a veteran of the U.S. Navy, honorably discharged as a Lieutenant Commander after serving eight years as a Naval Medical Officer.  

About Ikaria, Inc.

Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support.

The INOMAX therapy package also is marketed in Puerto Rico, Canada, Australia, Mexico and Japan. The company is investigating additional indications for INOMAX in bronchopulmonary dysplasia, and for inhaled nitric oxide with the INOpulse® DS drug-delivery system as a drug-device combination product in pulmonary arterial hypertension (PAH) and chronic obstructive pulmonary disease (COPD). Ikaria's late-stage pipeline is also comprised of LUCASSIN® (terlipressin), a potential treatment for Hepatorenal Syndrome Type 1; as well as Bioabsorbable Cardiac Matrix (BCM), a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with a research facility in Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI.  Please visit www.ikaria.com.

 

Company Contact:
Samina Bari   
Ikaria, Inc.   
(908) 238-6372   
samina.bari@ikaria.com

Media Contact:   
Claire Sojda   
Tiberend Strategic Advisors, Inc.
(212) 827-0020   
csojda@tiberend.com

 

 


'/>"/>
SOURCE Ikaria, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
2. Ikaria® to Present at 14th Annual BIO CEO & Investor Conference
3. Ikaria® to Present at 2011 BIO Investor Forum
4. Ikaria® To Present at 2011 BIO Business Forum and International Convention
5. Campbell Alliance Launches Market Research and Analytics Group, Appoints Michael Turner as General Manager of Encuity Research
6. Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
7. Laureate Biopharma Appoints Les Mintzmyer, Vice President, Operations
8. InspireMD Appoints Dr. James Barry to Its Board of Directors
9. Veracyte Appoints Mark Spring as Chief Financial Officer
10. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
11. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
Breaking Biology Technology:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
Breaking Biology News(10 mins):